MAPT and synucleinopathy: These studies suggest that lysosomal PGRN regulates not only TDP-43 but also other proteinopathies, especially tau- and synucleinopathy, and therefore may be a common therapeutic target for multiple proteinopathies in neurodegenerative diseases.